• 1. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 5. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles Benzodioxoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzodioxoles

Recent Advances in the Study of 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid (CAS: 24351-54-0) and Its Applications in Chemical Biology and Medicine

2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid (CAS: 24351-54-0) is a compound of significant interest in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive molecules, particularly in the development of novel anti-inflammatory and anticancer agents. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, synthetic pathways, and biological activities.

One of the most notable advancements in the study of 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid is its application in the design of small-molecule inhibitors targeting specific enzymes involved in inflammatory pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects on cyclooxygenase-2 (COX-2), an enzyme implicated in inflammation and pain. The researchers utilized molecular docking and kinetic assays to elucidate the binding interactions, revealing a high affinity for the COX-2 active site.

In addition to its anti-inflammatory potential, recent research has also investigated the anticancer properties of 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid derivatives. A study in Bioorganic & Medicinal Chemistry Letters (2024) reported that certain modifications to the biphenyl core structure enhanced the compound's ability to induce apoptosis in cancer cell lines, particularly those resistant to conventional chemotherapy. The mechanism of action was linked to the disruption of mitochondrial membrane potential and activation of caspase-dependent pathways.

The synthetic accessibility of 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid has also been a focus of recent research. A team from the University of Cambridge developed a novel, scalable synthesis route that improves yield and reduces byproducts, as detailed in a 2023 Organic Process Research & Development publication. This advancement is expected to facilitate the large-scale production of derivatives for further preclinical and clinical studies.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid derivatives. A 2024 review in Drug Discovery Today emphasized the need for further structural modifications to enhance bioavailability and reduce off-target effects. Computational modeling and high-throughput screening are being employed to address these limitations, with several candidates currently in early-stage development.

In conclusion, 2-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid (CAS: 24351-54-0) represents a versatile scaffold with significant potential in drug discovery. Recent studies have expanded our understanding of its biological activities and synthetic pathways, paving the way for future therapeutic applications. Continued research efforts are expected to yield more optimized derivatives with improved efficacy and safety profiles, positioning this compound as a valuable tool in chemical biology and medicine.

• 61441-07-4(1,3-Benzodioxole-5-carboxylic acid, 6-(2-methylphenyl)-, methyl ester)
• 24351-56-2(3',4'-(Methylenedioxy)-3-biphenylcarboxylic Acid)
• 1261960-47-7(5-Methoxy-3-(3,4-methylenedioxyphenyl)benzoic acid)
• 1258628-34-0(5-Hydroxy-3-(3,4-methylenedioxyphenyl)benzoic acid)
• 61440-96-8(Benzoic acid, 2-[6-(hydroxymethyl)-1,3-benzodioxol-5-yl]-)
• 5025-54-7(6-methyl-1,3-dioxaindane-5-carboxylic acid)
• 105868-34-6(Bifendate Dicarboxylic Acid)
• 61440-99-1(1,3-Benzodioxole-5-carboxylic acid, 6-[2-(hydroxymethyl)phenyl]-)
• 193151-97-2(4-Biphenyl-1,3Dioxol-5-Yl-Carboxylic Acid)
• 139058-87-0(1,3-Benzodioxole-5-carboxylic acid,4-(2-carboxy-4,5-dimethoxyphenyl)-)